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Background: The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for preventing
venous thromboembolism (VTE) after lumbar spine surgery.
Methods: In this randomized, controlled study, 665 patients who underwent lumbar surgery were randomly
assigned to receive either rivaroxaban or parnaparin. Rivaroxaban and parnaparin were used for preventing
postoperative venous thrombosis. The occurrence of postoperative efficacy endpoint events (venous thrombosis)
and safety endpoint events (hemorrhage) was compared for each group.
Results: Efficacy endpoint results: in the rivaroxaban group, there were 6 thrombotic events (1.7 %), 2 cases with
severe VTE (0.6 %), and 3 cases with symptomatic VTE (0.9 %). In the parnaparin group, there were 10 thrombotic
events (3.1 %), 4 cases with severe VTE (1.2 %), and 6 cases with symptomatic VTE (1.9 %). Safety endpoint results: in
the rivaroxaban group, there were 21 cases with bleeding events (6.2 %), 2 cases with severe bleeding (0.6 %), and
19 cases with non-severe bleeding (5.6 %). In the parnaparin group, there were 21 bleeding events (6.2 %), 1 case
with severe bleeding (0.3 %), and 16 cases with non-severe bleeding (4.9 %). The incidences of thromboembolic
events, including severe and symptomatic VTE, were not significantly different between the two groups (P > 0.05).
Bleeding event rates, including severe and non-severe bleeding, were also not significantly different.
Conclusions: Rivaroxaban proved to be equally effective as parnaparin for anticoagulation therapy, with both drugs
exhibiting a similar prevention effect against postoperative VTE after lumbar spine surgery, without increasing the
risk of postoperative bleeding.
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Deep venous thrombosis (DVT) is one of the more com-
mon and dangerous complications of spinal surgery, as it
can result in a fatal pulmonary embolism (PE) [1, 2]. The
American College of Chest Physicians (ACCP) [2] and the
National Institute for Health and Care Excellence (NICE)
[3] recommend the use of low-molecular-weight heparin
and low-dose common heparin for preventing venous
thromboembolism (VTE) among patients who underwent
selective surgery and those who suffer from spinal cord in-
jury, and thus are at risk for VTE. Glotzbecker [4]* Correspondence: yanpingzhengcn@163.com
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creativecommons.org/publicdomain/zero/1.0/reported that a questionnaire assessing anticoagulant
choice among 94 spinal surgeons surveyed revealed that
58 % of surgeons prefer low-molecular-weight heparin as
the first choice. Low-molecular-weight heparin is consid-
ered the gold standard anticoagulant therapy after spinal
surgery because it exerts minimal effects on platelet func-
tion and thus has an insignificant influence on the early
stages of hemostasis and does not increase the bleeding
risk. However, one disadvantage of low-molecular-weight
heparin is that it requires subcutaneous absorption. Many
patients cannot tolerate the complications caused by long-
term subcutaneous injections. Rivaroxaban, a novel oral
anticoagulant, has been clinically used following ortho-
pedic surgery, particularly for preventing VTE after re-
placement surgery of the hip and knee. Althoughdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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report has been published that describes the efficacy and
safety of its anticoagulation ability after spinal surgery.
The objective of this study is to evaluate the effectiveness
and safety of rivaroxaban for preventing VTE after lumbar
spine surgery, compared with parnaparin.
Materials and methods
Clinical data
The sample size was based on a power analysis with the
values α = 0.05, β = 0.1, power = 0.9, and an effect size
P = 0.8 for parnaparin and P = 0.9 for rivaroxaban.
These parameters required a sample size of Z = 131 for
the two groups. Including a withdrawal rate of 20 % sug-
gests that 158 cases should be included.
This clinical trial was a prospective randomized con-
trolled trial that included 978 patients who underwent
lumbar surgery between August 2009 and December
2012. According to the high-risk factors of spinal surgery
presented in the 7th ACCP vein thrombosis prevention
guidelines [2], all cases selected had one of the following
high-risk factors for VTE in spinal surgery: 1) age ≥60
years; 2) body mass index (BMI) ≥30 kg/m2; 3) thrombo-
philia, including conditions such as hypertension, diabetes,
hyperlipidemia, cancer, and others; 4) previous history of
venous thrombosis; 5) anterior or combined anterior–pos-
terior procedure; and 6) spinal trauma or spinal cord dam-
age. Meanwhile, case exclusion criteria included 1) oral
anticoagulant therapy 3 months prior to the operation; 2)
vein thrombosis on preoperative B-ultrasound; 3) preopera-
tive urinalysis positive for red blood cells, fecal occult blood,
skin purpura, or hematoma; 4) active bleeding or high risk
of bleeding; and 5) contraindication towards rivaroxaban
and parnaparin or patients whose parnaparin dose needed
to be adjusted. A total of 665 cases met these criteria and
were selected for the experiment. This study was conducted
in accordance with the declaration of Helsinki. This study
was conducted with approval from the Ethics Committee
of Qilu Hospital of Shandong University. Written informed
consent was obtained from all participants.
Grouping
Two groups of envelopes were pre-prepared and labeled
with: group A: rivaroxaban and group B: parnaparin. Pa-
tients randomly selected one envelope upon admission.
Therefore, patients were divided into two groups: the
rivaroxaban group (341 cases) and the parnaparin group
(324 cases).
Prevention
Patients in group A began daily oral treatment with 10 mg
rivaroxaban (Bayer Schering Pharma AG, Leverkusen,
D-51368, Germany) 6 to 8 h after surgery, and the treat-
ment continued until the 14th day, when the patientscould fully ambulate. Patients in group B received sub-
cutaneous injections of 40 mg parnaparin (Sanofi-Aventis,
France 1–13, Boulevard Romain Rolland 75014 Paris,
France) 6 to 8 h after surgery and once per day until the
14th day, when they could fully ambulate.
The study team was composed of researchers from the
departments of hematology, anesthesiology, spine sur-
gery, cardiology, pneumology, and ultrasound, along
with clinical pharmacists, who participated in the treat-
ment of complications.
Observation indicators
Patients were monitored every day for symptoms and
signs of DVT or PE. The symptoms of DVT included leg
swelling, lower extremity pain, and Homans sign. If a
symptom or sign was observed, Doppler ultrasound was
performed immediately on the bilateral veins of the
lower extremities. Symptoms that suggested PE included
sudden-onset dyspnea, retrosternal pain, hemoptysis,
cyanosis, syncope, profuse sweating, cold limbs, and con-
vulsions. If these were observed, electrocardiography was
performed immediately to eliminate other possible condi-
tions, such as myocardial infarction. Spiral computed tom-
ography (CT) was conducted as soon as possible to
determine pulmonary angiography. Post discharge, pa-
tients were told to inform their caregiver if they experi-
enced any signs and symptoms of DVT or PE. If present,
the ultrasound procedure was immediately performed.
Asymptomatic patients also underwent Doppler ultra-
sound on the bilateral deep veins of the lower extremities
on the 2nd, 7th, and 14th days of treatment and on the
4th week after the treatment ended. DVT in any area
(proximal and distal), non-fatal PE, and the number of pa-
tient deaths were recorded.
Efficacy endpoint indicator
The primary efficacy endpoint was a combined endpoint
comprising all DVT, non-fatal PE, and mortality from all
causes during the treatment period (until the 14th day).
The secondary efficacy endpoint was a combined endpoint
composed of severe VTE, i.e., proximal DVT, non-fatal
PE, and VTE-induced death during the treatment period
(until the 14th day). Other efficacy endpoints included the
occurrence of symptomatic VTE during treatment and
follow-up and deaths during the follow-up period.
Safety endpoint indicator
The primary safety endpoint was major bleeding events
during the treatment. Severe bleeding was defined as
fatal bleeding, bleeding in inflow critical organs (such as
the posterior peritoneum, intracranium, intraocular, and
intraspinal canal), bleeding-induced reoperation, or clin-
ically significant bleeding outside the surgical site with a
decrease of ≥20 g/L in hemoglobin level (with the level
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the need to transfuse ≥2 units of whole blood or packed
red blood cells. The other safety endpoints included all
non-serious bleeding (i.e., all events that were not evalu-
ated as severe bleeding, such as skin bruising, gastrointes-
tinal bleeding, fecal occult blood, and urine erythrocytes)
during the treatment and bleeding wound complications
(a composite indicator of wound hematoma and surgical
site bleeding).
Statistical analysis
SPSS 13.0.1 software was used for statistical analysis. The
χ2 test was employed for comparing the incidence rates of
thromboembolic and bleeding events between the two
groups. If the number of cases was ≥5, then the χ2 test
was used. If the number of cases was <5, then the cor-
rected χ2 test was used. If the number of cases was ≤1,




In the rivaroxaban group, six thrombotic events oc-
curred (1.7 % of cases). In one case, the patient exhibited
femoral vein thrombosis, floating blood clots, and a
swollen leg. In another case, the patient demonstrated
external iliac vein thrombosis, a swollen leg, difficulty
breathing, and a progressive decline in arterial oxygen
pressure. Pulmonary artery CT angiography confirmed
left upper lobe artery embolization. In another case, the
patient had an anterior tibial vein embolism without
clinical symptoms. Two cases presented posterior tibial
vein thrombosis. In one of these cases, the patient expe-
rienced leg swelling and discomfort; in the second case,
the patient suffered from peroneal vein thrombosis with-
out clinical symptoms.Table 1 Occurrence rate of thrombus (efficacy endpoint)
Efficacy endpoint Rivaroxaban group (case number/total n
Primary efficacy endpoint 6/341 (1.7 %)
Death 0/341 (0.0 %)
Non-fatal pulmonary embolism 1/341 (0.3 %)
DVT 6/341 (1.7 %)
Proximal end 2/341 (0.6 %)
Distal end only 4/341 (1.2 %)
Severe VTEa 2/341 (0.6 %)
Symptomatic VTEb 3/341 (0.9 %)
During the treatment 3/341 (0.9 %)
During the follow-up 0/277 (0.0 %)
Death during the follow-up 0/277 (0.0 %)
*Used the corrected χ2 test
aSevere VTE was the combined turnover, composing of proximal DVT formation, no
bSymptomatic VTE included any symptomatic DVT formation (proximal or distal) anIn the parnaparin group, 10 thrombotic events occurred
(3.1 % of cases). In one case, the patient suffered from ex-
ternal iliac vein and femoral vein thrombosis and suddenly
lost consciousness on the 7th day. Lower-extremity B-
ultrasound revealed left external iliac vein and femoral
vein thrombosis. Heart B-ultrasound revealed pulmonary
hypertension, which led to the diagnosis of PE as the
cause of death. Femoral vein thrombosis occurred in three
cases. In one case, the patient had a swollen leg and diffi-
culty breathing, with a progressive decline in arterial oxy-
gen pressure. This case was considered a non-fatal PE.
The patients in the other two cases experienced lower
limb swelling and pain. Four cases had peroneal vein
thrombosis without clinical symptoms. One case exhibited
posterior tibial vein thrombosis with leg pain. During the
follow-up period, one case of femoral vein thrombosis
with lower limb swelling occurred.
No significant difference was found in the incidence
rates of thromboembolic events between the two groups
(P > 0.05). The incidence rates of severe and symptomatic
VTE also exhibited no significant difference (P > 0.05,
Table 1).
There were 298 patients who were older than 60 years
of age in this clinical trial, and among these, 12 patients
(4.0 %) experienced DVT. There were 304 patients with a
BMI ≥30 kg/m2, among whom 9 (3.0 %) experienced
DVT. There were 201 patients who had thrombophilia; of
these, 55 cases had diabetes, 2 of whom (3.6 %) experi-
enced DVT; 65 cases had hypertension, 1 of whom (1.5 %)
experienced DVT; 20 cases had hyperlipidemia, 1 of
whom (5.0 %) had DVT; 32 patients had a combination of
2 of these conditions (diabetes, hypertension, and hyper-
lipidemia) 2 (6.3 %) of whom also had DVT; 29 cases had
spinal tumors, 3 of whom (10.3 %) experienced DVT; and
7 patients had a previous history of venous thrombosis, 1
of whom (14.3 %) experienced DVT. Anterior orumber) Parnaparin group (case number/total number) P value






4/324 (1.2 %) >0.25*




nfatal pulmonary embolism, and VTE-induced death
d nonfatal/fatal symptomatic pulmonary embolism
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16 patients, and 1 of these (6.3 %) experienced DVT. Fur-
thermore, 86 cases had spinal trauma; 55 cases had no
nerve injury, 1 of whom (1.8 %) experienced DVT; and 31
cases had nerve injury, 4 of whom (12.6 %) experienced
DVT (Table 2).
Among the 665 patients, anterior surgery was per-
formed in 12 cases (none experienced DVT); anterior–
posterior combination surgery was performed in 4 cases
(1 experienced DVT), and in this case vertebral tumor
section + intra-fixation was performed. Of the other 649
surgery cases, 15 experienced DVT: 2 cases of discec-
tomy, 3 cases of spinal dilatation decompression, 5 cases
of fracture reduction (or decompression) intrafixation, 1
case of transforaminal interbody fusion, 1 case of poster-
ior interbody fusion, 2 cases of vertebral tumor resection
intrafixation, and 1 case of a secondary overhauling op-
eration. The secondary overhauling operation included:
5 cases of posterior interbody fusion after the post-disc
surgery recurrence, 1 case of a posterior overhauling op-
eration and DVT occurrence (this patient did not heal 6
months after the fracture surgery and exhibited an auto-
nomic nerve fracture), and 1 case of a second focus
cleaning because DVT occurred within 1 year of tuber-
culose focus cleaning interbody intrafixation (Table 3).
Safety endpoint results
In the rivaroxaban group, 21 cases (6.2 %) experienced
bleeding events, with 2 cases of severe bleeding. In one
of the severe bleeding cases, a reoperation for epidural
hematoma-induced neurological dysfunction was per-
formed on the 4th postoperative day. In the other case,
the patient needed a reoperation for an arterial bleeding-
induced edge hematoma on the 4th postoperative day. ATable 2 Distribution of VTE risk factors in DVT patients
VTE risk factor DVT cases
Rivaroxaban group (6)
Age ≥60 years old 5







Previous history of phlebothrombosis 1
Anterior or combined anterior–posterior surgery 0
Spinal trauma 2
Without nerve injury 0
With nerve injury 2total of 19 cases of non-serious bleeding were observed.
Six of these cases occurred in the subcutaneous large ec-
chymosis outside the incision site; 7 cases involved inci-
sion bleeding (with 3 cases being infected); 5 cases were
suspected gastrointestinal bleeding (with positive fecal
occult blood); and the urinalysis result of 1 case was
positive for red blood cells.
In the parnaparin group, 17 patients (5.2 %) experi-
enced bleeding events. In one case, the patient suffered
from severe bleeding that was likely caused by a gastro-
intestinal bleeding event (e.g., vomiting, bloody diarrhea)
and low hemoglobin (70 g/L) level. This patient was
transfused with four units of red blood cells. Further-
more, 16 cases of non-serious bleeding were observed.
Among these, 2 were cases of spontaneous hematoma
outside the incision sites, 4 were cases of large-area of
ecchymosis, and 4 were cases of bleeding incision (with
2 cases being infected). Four patients were suspected of
having alimentary tract hemorrhage, with positive fecal
occult blood. The urinalysis results of 2 cases were posi-
tive for red blood cells.
No significant difference was found in the bleeding
rates of the thromboembolic events between the two
groups (P > 0.05), with severe bleeding and non-severe
bleeding also showing no statistically significant differ-
ences (P > 0.05, Table 4).
Discussion
DVT is one of the more common and dangerous com-
plications of spinal surgery, as it may cause fatal PE [1,
2]. Many factors contribute to VTE after spinal surgery,
including 1) age ≥60 years; 2) BMI ≥30 kg/m2; 3) throm-
bophilia, including conditions such as hypertension, dia-
betes, hyperlipidemia, cancer, or others; 4) previousTotal cases
enrolled (665)
Ratio of DVT
incidence 2.4 %LWMH group (10) Sum (16)
7 12 298 4.0 %
6 9 304 3.0 %
4 6 201 3.0 %
1 2 55 3.6 %
1 1 65 1.5 %
0 1 20 5.0 %
0 2 32 6.3 %
2 3 29 10.3 %
0 1 7 14.3 %
1 1 16 6.3 %
3 5 86 5.8 %
1 1 55 1.8 %
2 4 31 12.9 %




Rivaroxaban (6) Low-molecular weight
heparin sodium (10)
Sum (16)
Anterior 12 0 0 0
Fracture reduction decompression intrafixation 6 0 0 0
Vertebral tumor section intrafixation 4 0 0 0
Tuberculose focus cleaning bone graft intrafixation 2 0 0 0
Anterior + posterior 4 0 1 1
Vertebral tumor section intrafixation 3 0 1 0
Tuberculose focus cleaning interbody intrafixation 1 0 0 0
Posterior 649 6 9 15
Vertebral tumor section 260 1 1 2
Spinal dilatation decompression 166 1 2 3
Fracture reduction (or decompression) intrafixation 80 2 3 5
Intervertebral foramen approach vertebral interbody fusion (TLIF) 52 0 1 1
Posterior vertebral interbody fusion (PLIF) 37 1 0 1
Tuberculose focus cleaning interbody intrafixation 8 0 0 0
Vertebral tumor section intrafixation 22 1 1 2
Vertebral tumor section 16 0 0 0
Second overhauling operation 8 0 1 1
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bined anterior–posterior procedure; and 6) spinal
trauma or spinal cord damage. There were also some
confounding factors related to the operation, such as
position (prone position leads to increased abdominal
pressure and DVT), anesthesia method (nerve block can
cause venous dilatation of the lower extremity, slowed
circulation, and DVT), and operation route (anteriorTable 4 Occurrence rate of bleeding (safety endpoint)
Bleeding events Rivarox
Any bleeding during the treatment 21 (6.2
Severe bleeding 2 (0.6 %
Fatal bleeding 0
Bleeding into important organs 1
Reoccurrence of surgical bleeding 1
Clinically obvious bleeding outside the surgical site 0
Induced hemoglobin decreasing 0
Induced blood transfusion ≥2 units 0
Non-severe bleeding 19 (5.6
Clinically related non-severe bleedinga 6
Bleeding incision complicationsb 7
Other non-severe bleeding 6
*Used Fisher’s exact test
aClinically related non-severe bleeding included multi-sites bleeding, spontaneous h
bBleeding incision complications was the combined indicator of big incision bleedinlumbar surgery always slows circulation, which carries a
high risk of DVT). At the 2009 Annual Meeting of the
North American Spine Society, certain postoperative
precautions were recommended after spinal surgery to
reduce the incidence of thrombotic events [5]. The
ACCP [2] and NICE [3] recommended the use of low-
molecular-weight heparin and low-dose common hep-
arin for preventing VTE among patients who underwentaban group Parnaparin group P value
%) 17 (5.2 %) >0.5











ematoma and big incision hematoma
g and surgical site bleeding
Du et al. Journal of Orthopaedic Surgery and Research  (2015) 10:78 Page 6 of 8a selective operation and who suffer from spinal cord in-
jury and thus are at risk of VTE. Low-molecular-weight
heparin was chosen as the first-line postoperative anticoa-
gulation drug and the gold standard for spinal surgery [4,
6]. However, low-molecular-weight heparin has the disad-
vantage of requiring subcutaneous absorption. Several
patients cannot tolerate the complications caused by
long-term subcutaneous injections. Rivaroxaban is a re-
cently developed oral anticoagulant. The use of rivarox-
aban has gradually extended to orthopedic surgery.
However, its efficacy for spinal surgery and postopera-
tive safety assessment has rarely been reported. Thus,
we evaluated the effectiveness and safety of rivaroxaban
for preventing VTE after lumbar spine surgery, com-
pared with parnaparin.
This study found the following efficacy endpoint re-
sults: in the rivaroxaban group: 6 cases of thrombotic
events (1.7 %), 2 cases of severe VTE (0.6 %), and 3 cases
of symptomatic VTE (0.9 %); in the parnaparin group:
10 cases of thrombotic events (3.1 %), 4 cases of severe
VTE (1.2 %), and 6 cases of symptomatic VTE (1.9 %).
The safety endpoint results are as follows: in the rivarox-
aban group: 21 cases of bleeding events (6.2 %), 2 cases
of severe bleeding (0.6 %), and 19 cases of non-severe
bleeding (5.6 %); in the parnaparin group: 21 cases of
bleeding events (6.2 %), 1 case of severe bleeding (0.3 %),
and 16 cases of non-severe bleeding (4.9 %). In this
study, the incidences of thromboembolic events, i.e., se-
vere and symptomatic VTE, were not significantly differ-
ent between the two groups (P > 0.05). Bleeding event
rates, i.e., severe and non-severe bleeding, were also not
significantly different. Therefore, rivaroxaban prevented
VTE to a similar degree as parnaparin after lumbar spine
surgery, without increasing the risk of postoperative
bleeding over that of parnaparin.
The pharmacological mechanism of rivaroxaban in-
volves directly antagonizing blood coagulation factor X
to achieve its anticoagulation properties. Rivaroxaban
exhibits high oral bioavailability. Drug trials show that
its anticoagulant response is predictable and thus does
not require monitoring. The results of completed phase
II and III clinical trials showed that rivaroxaban exhibits
excellent DVT prevention after hip or knee replacement
surgery. One study that used rivaroxaban as the routine
anticoagulation therapy for 3449 cases of hip and knee
replacement surgeries showed that rivaroxaban displayed
similar anti-thrombotic efficacy to classic heparin but
did not increase the risk of bleeding [7]. Given that it is
easy to administer, does not require long-term labora-
tory parameter monitoring, and possesses other unique
advantages, the use of rivaroxaban has gradually ex-
tended to orthopedic surgery. However, reports describ-
ing its efficacy and postoperative safety assessment after
spinal surgery are rare.Early postoperative use of anticoagulant drugs may cause
hemorrhagic events, such as increased incision bleeding,
formation of a wound hematoma, and intraspinal
hematoma, thus increasing the postoperative risk [8, 9].
This is the main reason why anticoagulants are not used
by several spine surgeons. Low-molecular-weight heparin
is considered the gold standard anticoagulant therapy after
spinal surgery because it exerts a minimal effect on platelet
function and thus has an insignificant influence on the
early stages of hemostasis and does not increase bleeding
risk [10]. Several reports, such as those by Hebbeler [11]
and Ploumis [12], confirmed that using low-molecular-
weight heparin after spinal surgery does not increase the
risks of incision bleeding and spinal hematoma formation.
Rivaroxaban, as an X factor antagonist, was reported to ex-
hibit rapid metabolism in the plasma in pharmacological
experiments. In addition, its anticoagulant response was
predictable, and thus, rivaroxaban would not cause a sig-
nificantly prolonged prothrombin time or activated partial
thromboplastin time. The study performed to determine
the optimal dosage of rivaroxaban for patients undergoing
major orthopedic surgeries found that there was a close
correlation between the pharmacokinetics and pharmaco-
dynamics of rivaroxaban, and that 10 mg rivaroxaban
(once daily) was a suitable dose in the phase III clinical
trial, without the need for dosage adjustment [13, 14].
The results of the completed clinical trial confirmed that
the prophylactic dose of rivaroxaban (10 mg oral, once
daily) for anticoagulation therapy after hip and knee re-
placement surgery successfully lowered the risk for DVT
and did not increase the risk of bleeding [15, 16].
Spinal epidural hematoma and its neurological seque-
lae are the most serious complications associated with
anticoagulation drugs in perioperative spinal surgery,
with a reported incidence ranging from 0.1 to 0.7 %
[10, 17, 18]. In the current clinical trial, one case (0.3 %)
of epidural hematoma was reported in the rivaroxaban
group. However, this complication also occurred in the
absence of an anticoagulant. The most prominent reason
for spinal epidural hematoma surgery is a coagulation
disorder with various causes, such as liver or kidney dis-
ease, alcohol abuse, or radiation or chemotherapy, which
can lead to spontaneous bleeding [19]. Using logistic re-
gression assessment risk factors, Kou et al. [17] posited
that only when a patient had coagulation disorders with
multiple steps would he or she be at a high risk for
spinal epidural hematoma. The typical symptom of
spinal epidural hematoma is progressive neurological
deficit, and it is not typical for back pain to be the only
symptom. In a study involving 13 reported cases of postop-
erative spinal epidural hematoma, Gerlach [10] found that
newly occurring neurological impairment occurred in ap-
proximately 77 % of such cases. Once spinal epidural
hematoma is diagnosed, early surgical decompression is the
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et al. [20] reported that nerve function could recover fully
within 8 h after the onset of symptoms with surgical de-
compression. Gerlach et al. [10] reported that the postoper-
ative nerve function of 60 % of patients who underwent
early surgical decompression could recover completely.
The remaining patients who suffered from postoperative
bleeding due to spinal cord injury were being treated with
anticoagulant drugs. In another study evaluating 476 spinal
cord injury patients, bleeding at surgical sites and in the
upper digestive tract accounted for 16 and 19 % of bleeding
complications, respectively [21]. No incidence of epidural
hematoma was reported.
The ACCP recommendations state that prevention is
no longer necessary for patients with selective spinal
surgery who do not have multiple risk factors [2]. How-
ever, the majority of patients who undergo spinal surgery
are elderly or have other risk factors. In this experiment,
the DVT incidence rates of the patients who had a pre-
vious history of phlebothrombosis, a combination of
spinal trauma and nerve injury, spinal tumor, or a com-
bination of two conditions out of diabetes, hypertension,
and hyperlipidemia, were 14.3, 12.9, 10.3, and 6.3 %, re-
spectively, indicating that these four factors were high-
risk factors for DVT after spinal surgery. These patients
should be given early postoperative parnaparin or rivar-
oxaban and intermittent pneumatic compression treat-
ment. The prevention of thrombosis among spinal
fracture patients often requires multidisciplinary expert-
ise, including spinal surgery and trauma surgery, from
physicians of various disciplines, to complete the treat-
ment. When no obvious endogenous or exogenous
bleeding tendency is observed, parnaparin and intermit-
tent pneumatic compression treatments should be ap-
plied as soon as possible to prevent VTE. Premature
chemoprophylaxis may increase the risk of bleeding
complications, such as epidural hematoma. However, the
risk/benefit ratio supports early prevention over observa-
tion. Therefore, physicians should be aware of the bleed-
ing tendencies of their patients. Once a diagnosis of
epidural hematoma is confirmed, early surgical decom-
pression will be more favorable for recovering nerve
function. Given the particularity of spinal surgery, once
a postoperative spinal hematoma is formed, the risks of
secondary damage to the spinal cord and nerves will un-
doubtedly increase, particularly in the cervical and thor-
acic spine where the effective volume of the spinal canal
is small. The hematoma event will undoubtedly increase
the chance of secondary nerve damage in a duplicative
manner. Given that no previous safety assessment of the
use of rivaroxaban as an anticoagulant therapy after
spinal surgery is available, we fully considered the risk of
spinal hematoma or bleeding-caused nerve damage dur-
ing anticoagulation when we designed the clinical trialsin this study. Because of this, we likely minimized the
risk of secondary neurological damage. Therefore, only
patients with lumbar cases were treated with rivaroxaban
in this initial safety study. Based on the analysis of ana-
tomical characteristics, the coccygeal nerve root of the
lower lumbar nerve exhibits a certain tolerance to exter-
nal compression due to complications, and the effective
volume of the lower lumbar spinal canal was relatively
large and had a buffer space. Therefore, the prompt re-
moval of the hematoma would result in a low probability
of irreversible neurological damage.
This study showed that, compared with parnaparin,
the new oral anticoagulant rivaroxaban was easy to ad-
minister and exhibited a reliable anticoagulant effect,
which could reduce postoperative thrombosis events in
patients at a high risk for VTE. Compared with parna-
parin, rivaroxaban did not increase the postoperative
bleeding risk during lumbar spine surgery. However, be-
cause of differences in spinal anatomy, the spinal cord
and cauda equina exhibited different tolerance levels to
external compression. Whether rivaroxaban can be ex-
tensively used in cervical and thoracic postoperative
anticoagulation still requires careful consideration and
should be validated using large-scale, multi-center, ran-
domized, and double-blind clinical trials.
Conclusions
In conclusion, VTE is a complication that can cause fatal
damage after spinal surgery (Table 1). This study found
four risk factors that presented the highest risk for post-
spine surgery VTE: previous history of venous throm-
bosis, spinal trauma associated with nerve injury, spinal
tumors, and the combination of two of three conditions
(diabetes, hypertension, or hyperlipidemia) (Table 2). Fi-
nally, this study demonstrated that rivaroxaban had a
similar efficacy as parnaparin for preventing postopera-
tive VTE after lumbar spine surgery, without increasing
the risk of postoperative bleeding (Table 4).
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